Cardiometabolic Care Maryland

The 2026 ESC guideline changes how clinicians classify and treat heart failure. It removes the intermediate HFmrEF category, expands reduced-ejection-fraction heart failure below 50%, and recommends SGLT2 inhibitors and appropriate mineralocorticoid-receptor antagonists across the symptomatic spectrum. The guideline also brings obesity treatment, blood-pressure control, kidney protection, sleep evaluation, exercise, and muscle preservation into one integrated cardiometabolic framework for modern, individualized heart-failure care across diverse patients.